Pawan G L, Semple S J
Lancet. 1983 Jan 1;1(8314-5):15-7. doi: 10.1016/s0140-6736(83)91560-x.
Sodium DL-3-hydroxybutyrate was administered to obese subjects (more than 150% ideal body-weight) who were either receiving a 2 . 5 MJ (600 kcal) diet containing 34 g protein on one day with a total fast (water and vitamins only) on the next day, for 21 days, or were undergoing therapeutic starvation for 14 days. Both intravenous and oral hydroxybutyrate significantly reduced net body protein loss as measured by total urinary nitrogen and 3-methylhistidine excretion. Hydroxybutyrate administration did not significantly affect the rate of weight-loss but seemed to increase the fat/lean ratio of the tissue loss. The subjects experienced no untoward effects and none complained of hunger while receiving 3-hydroxybutyrate.
向肥胖受试者(超过理想体重的150%)给予DL-3-羟基丁酸钠,这些受试者要么在一天接受含34克蛋白质的2.5兆焦(600千卡)饮食,次日完全禁食(仅饮水和维生素),持续21天,要么接受14天的治疗性饥饿。通过总尿氮和3-甲基组氨酸排泄量测量,静脉注射和口服羟基丁酸盐均显著减少了机体净蛋白质损失。给予羟基丁酸盐对体重减轻速率没有显著影响,但似乎增加了组织损失的脂肪/瘦肉比例。受试者在接受3-羟基丁酸盐时未出现不良影响,也没有人抱怨饥饿。